文献速递角膜与眼表疾病

类风湿关节炎相关周边溃疡性角膜炎早期免疫抑制治疗后的结局

Rheumatoid arthritis-associated peripheral ulcerative keratitis outcomes after early immunosuppressive therapy.
PubMed 文献 · Br J Ophthalmol · 2022-04-13

单中心回顾性比较队列研究纳入36例患者52眼,评估早期免疫抑制治疗(发病4周内给药)对类风湿关节炎相关周边溃疡性角膜炎的作用。早期治疗组37眼(71.2%)较未早期治疗组15眼(28.8%)更易实现早期炎症控制、复发更少且视力结局更好,早期治疗为复发的保护因素(HR 0.345)。

要点

  • 早期免疫抑制治疗(4周内)为周边溃疡性角膜炎复发的保护因素(HR 0.345,95%CI 0.126-0.946,p=0.039)。
  • 晚于4周治疗(OR 7.75)、首诊未诊断类风湿关节炎(OR 4.14)及至少一次复发(OR 6.42)为视力丧失危险因素。
  • 早期治疗组更易实现早期炎症控制、复发更少且视力结局更好。

核心结论

  • 暴露于早期免疫抑制治疗的类风湿关节炎相关周边溃疡性角膜炎眼更可能实现早期炎症控制、复发更少且视力结局更好。

研究设计与样本

  • 单中心、回顾性、比较性队列研究,纳入36例患者的52眼,分为早期免疫抑制治疗暴露组(37眼,71.2%)与未暴露组(15眼,28.8%),早期治疗定义为周边溃疡性角膜炎发病4周内给药。

主要发现

  • 随访时间41.2+53.3个月(范围4-236个月)。
  • 早期免疫抑制治疗为周边溃疡性角膜炎复发的保护因素(HR 0.345,95%CI 0.126-0.946,p=0.039)。
  • 周边溃疡性角膜炎发病后晚期诊断类风湿关节炎(HR 4.93,95%CI 1.75-13.85,p=0.002)和炎症控制延迟≥2个月(HR 8.37,95%CI 1.88-37.16,p=0.005)为复发的危险因素。
  • 晚期免疫抑制治疗(OR 7.75,95%CI 2.00-29.99,p=0.003)、首诊时类风湿关节炎诊断不明(OR 4.14,95%CI 1.15-14.91,p=0.030)和至少一次周边溃疡性角膜炎复发(OR 6.42,95%CI 1.71-24.07,p=0.006)为视力丧失的危险因素。
  • 生存分析显示早期免疫抑制治疗暴露眼周边溃疡性角膜炎复发风险更低(p=0.039)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To evaluate the role of early immunosuppressive therapy (IMT) in the management of rheumatoid arthritis (RA)-associated peripheral ulcerative keratitis (PUK). METHODS: Single-centre, retrospective, comparative cohort study. Patients with RA-associated PUK were divided into two groups; those exposed to and those not exposed to early IMT, defined as administrating therapy within the first 4 weeks from the PUK onset. Outcomes included PUK recurrence, control of inflammation and development of ocular complications, including corneal scarring and perforation, cataract formation or progression and permanent visual loss. RESULTS: A total of 52 eyes from 36 patients were included for analysis; 37 (71.2%) eyes received early IMT and 15 (28.8%) eyes did not. Follow-up time was 41.2+53.3 months (range: 4-236 months). While early IMT was a protective factor (HR 0.345, 95% CI 0.126 to 0.946, p=0.039), late RA diagnosis after PUK onset (HR 4.93, 95% CI 1.75 to 13.85, p=0.002) and retarded (≥2 months) control of inflammation (HR 8.37, 95% CI 1.88 to 37.16, p=0.005) were risk factors for PUK recurrence. Late IMT (OR 7.75, 95% CI 2.00 to 29.99, p=0.003), an unknown diagnosis of RA at first visit (OR 4.14, 95% CI 1.15 to 14.91, p=0.030) and at least one PUK recurrence (OR 6.42, 95% CI 1.71 to 24.07, p=0.006) were risk factors for visual loss. Survival analysis rendered eyes exposed to early IMT a lower risk of PUK recurrence (p=0.039). CONCLUSION: Eyes with RA-associated PUK exposed to early IMT were more likely to achieve earlier inflammatory control, fewer recurrences and had better visual outcomes.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ruiz-Lozano RE, Ramos-Davila EM, Garza-Garza LA, et al. Rheumatoid arthritis-associated peripheral ulcerative keratitis outcomes after early immunosuppressive therapy. Br J Ophthalmol. 2022. PMID: 35418476. doi:10.1136/bjophthalmol-2022-321132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。